-
1
-
-
0033646209
-
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan
-
Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000; 32: 1224-1229.
-
(2000)
Hepatology
, vol.32
, pp. 1224-1229
-
-
Arii, S.1
Yamaoka, Y.2
Futagawa, S.3
-
2
-
-
17344368270
-
Early hepatocellular carcinoma as an entity with a high rate of surgical cure
-
DOI 10.1002/hep.510280511
-
Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998; 28: 1241-1246. (Pubitemid 28493833)
-
(1998)
Hepatology
, vol.28
, Issue.5
, pp. 1241-1246
-
-
Takayama, T.1
Makuuchi, M.2
Hirohashi, S.3
Sakamoto, M.4
Yamamoto, J.5
Shimada, K.6
Kosuge, T.7
Okada, S.8
Takayasu, K.9
Yamasaki, S.10
-
3
-
-
38649141497
-
Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?
-
DOI 10.1002/hep.21933
-
Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008; 47: 82-89. (Pubitemid 351171044)
-
(2008)
Hepatology
, vol.47
, Issue.1
, pp. 82-89
-
-
Livraghi, T.1
Meloni, F.2
Di Stasi, M.3
Rolle, E.4
Solbiati, L.5
Tinelli, C.6
Rossi, S.7
-
4
-
-
84859586321
-
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors
-
Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107: 569-577.
-
(2012)
Am J Gastroenterol
, vol.107
, pp. 569-577
-
-
Shiina, S.1
Tateishi, R.2
Arano, T.3
-
5
-
-
84855314307
-
Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report
-
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012; 13: e11-e22.
-
(2012)
Lancet Oncol
, vol.13
-
-
Clavien, P.A.1
Lesurtel, M.2
Bossuyt, P.M.3
Gores, G.J.4
Langer, B.5
Perrier, A.6
-
6
-
-
4344652107
-
Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan
-
Todo S, Furukawa H,. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004; 240: 451-459.
-
(2004)
Ann Surg
, vol.240
, pp. 451-459
-
-
Todo, S.1
Furukawa, H.2
-
7
-
-
0031048958
-
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
-
DOI 10.1023/A:1008285123736
-
Simonetti RG, Liberati A, Angiolini C, Pagliaro L,. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997; 8: 117-136. (Pubitemid 27112878)
-
(1997)
Annals of Oncology
, vol.8
, Issue.2
, pp. 117-136
-
-
Simonetti, R.G.1
Liberati, A.2
Angiolini, C.3
Pagliaro, L.4
-
8
-
-
0032765871
-
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
-
Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999; 5: 1676-1681. (Pubitemid 29334445)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.7
, pp. 1676-1681
-
-
Leung, T.W.T.1
Patt, Y.Z.2
Lau, W.-Y.3
Ho, S.K.W.4
Yu, S.C.H.5
Chan, A.T.C.6
Mok, T.S.K.7
Yeo, W.8
Liew, C.-T.9
Leung, N.W.Y.10
Tang, A.M.Y.11
Johnson, P.J.12
-
9
-
-
27144557565
-
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
-
DOI 10.1093/jnci/dji315
-
Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97: 1532-1538. (Pubitemid 41631953)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.20
, pp. 1532-1538
-
-
Yeo, W.1
Mok, T.S.2
Zee, B.3
Leung, T.W.T.4
Lai, P.B.S.5
Lau, W.Y.6
Koh, J.7
Mo, F.K.F.8
Yu, S.C.H.9
Chan, A.T.10
Hui, P.11
Ma, B.12
Lam, K.C.13
Ho, W.M.14
Wong, H.T.15
Tang, A.16
Johnson, P.J.17
-
10
-
-
0037080414
-
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
-
DOI 10.1002/cncr.10236
-
Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002; 94: 421-427. (Pubitemid 34081372)
-
(2002)
Cancer
, vol.94
, Issue.2
, pp. 421-427
-
-
Leung, T.W.T.1
Tang, A.M.Y.2
Zee, B.3
Yu, S.C.H.4
Lai, P.B.S.5
Lau, W.Y.6
Johnson, P.J.7
-
11
-
-
18744373048
-
Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma
-
Yin XY, Lu MD, Liang LJ, Lai JM, Li DM, Kuang M,. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 2526-2529. (Pubitemid 40667995)
-
(2005)
World Journal of Gastroenterology
, vol.11
, Issue.16
, pp. 2526-2529
-
-
Yin, X.-Y.1
Lu, M.-D.2
Liang, L.-J.3
Lai, J.-M.4
Li, D.-M.5
Kuang, M.6
-
12
-
-
9444277289
-
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy
-
DOI 10.1093/annonc/mdh430
-
Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004; 15: 1661-1666. (Pubitemid 39562607)
-
(2004)
Annals of Oncology
, vol.15
, Issue.11
, pp. 1661-1666
-
-
Yeo, W.1
Lam, K.C.2
Zee, B.3
Chan, P.S.K.4
Mo, F.K.F.5
Ho, W.M.6
Wong, W.L.7
Leung, T.W.T.8
Chan, A.T.C.9
Ma, B.10
Mok, T.S.K.11
Johnson, P.J.12
-
13
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
14
-
-
0037087696
-
Simplified staging for hepatocellular carcinoma
-
DOI 10.1200/JCO.20.6.1527
-
Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002; 20: 1527-1536. (Pubitemid 34260532)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.6
, pp. 1527-1536
-
-
Vauthey, J.-N.1
Lauwers, G.Y.2
Esnaola, N.F.3
Do, K.-A.4
Belghiti, J.5
Mirza, N.6
Curley, S.A.7
Ellis, L.M.8
Regimbeau, J.-M.9
Rashid, A.10
Cleary, K.R.11
Nagorney, D.M.12
-
15
-
-
0031424749
-
Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study
-
DOI 10.1016/S0959-8049(97)00163-9, PII S0959804997001639
-
Bobbio-Pallavicini E, Porta C, Moroni M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer. 1997; 33: 1784-1788. (Pubitemid 28129204)
-
(1997)
European Journal of Cancer
, vol.33
, Issue.11
, pp. 1784-1788
-
-
Bobbio-Pallavicini, E.1
Porta, C.2
Moroni, M.3
Bertulezzi, G.4
Civelli, L.5
Pugliese, P.6
Nastasi, G.7
-
16
-
-
0024581695
-
Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection
-
Lai KH, Tsai YT, Lee SD, et al. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol. 1989; 23: 54-56.
-
(1989)
Cancer Chemother Pharmacol
, vol.23
, pp. 54-56
-
-
Lai, K.H.1
Tsai, Y.T.2
Lee, S.D.3
-
17
-
-
12444293395
-
Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma
-
Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res. 2003; 23: 1891-1897. (Pubitemid 36750863)
-
(2003)
Anticancer Research
, vol.23
, Issue.2
, pp. 1891-1897
-
-
Tanioka, H.1
Tsuji, A.2
Morita, S.3
Horimi, T.4
Takamatsu, M.5
Shirasaka, T.6
Mizushima, T.7
Ochi, K.8
Kiura, K.9
Tanimoto, M.10
-
18
-
-
1642613800
-
Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma
-
Zaniboni A, Simoncini E, Marpicati P, Marini G,. Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. Br J Cancer. 1988; 57: 319. (Pubitemid 18096346)
-
(1988)
British Journal of Cancer
, vol.57
, Issue.3
, pp. 319
-
-
Zaniboni, A.1
Simoncini, E.2
Marpicati, P.3
Marini, G.4
-
19
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
20
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
21
-
-
0035134510
-
Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma
-
DOI 10.1097/00000658-200102000-00013
-
Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg. 2001; 233: 236-241. (Pubitemid 32106078)
-
(2001)
Annals of Surgery
, vol.233
, Issue.2
, pp. 236-241
-
-
Lau, W.-Y.1
Leung, T.W.T.2
Lai, B.-S.3
Liew, C.-T.4
Ho, S.K.W.5
Yu, S.C.H.6
Tang, A.M.Y.7
-
22
-
-
0037129704
-
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial
-
DOI 10.1016/S0140-6736(02)08649-X
-
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739. (Pubitemid 34607087)
-
(2002)
Lancet
, vol.359
, Issue.9319
, pp. 1734-1739
-
-
Llovet, J.M.1
Real, M.I.2
Montana, X.3
Planas, R.4
Coll, S.5
Aponte, J.6
Ayuso, C.7
Sala, M.8
Muchart, J.9
Sola, R.10
Rodes, J.11
Bruix, J.12
-
23
-
-
0036237822
-
Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma
-
DOI 10.1053/jhep.2002.33156
-
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35: 1164-1171. (Pubitemid 34454013)
-
(2002)
Hepatology
, vol.35
, Issue.5
, pp. 1164-1171
-
-
Lo, C.-M.1
Ngan, H.2
Tso, W.-K.3
Liu, C.-L.4
Lam, C.-M.5
Poon, R.T.-P.6
Fan, S.-T.7
Wong, J.8
-
24
-
-
80053974116
-
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
-
Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011; 29: 3892-3899.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3892-3899
-
-
Kaseb, A.O.1
Morris, J.S.2
Hassan, M.M.3
-
25
-
-
77955973284
-
Advanced hepatocellular carcinoma: Which staging systems best predict prognosis?
-
Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010; 28: 2889-2895.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2889-2895
-
-
Huitzil-Melendez, F.D.1
Capanu, M.2
O'Reilly, E.M.3
-
26
-
-
0031782818
-
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
-
Cancer of the Liver Italian Program (CLIP) investigators
-
Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998; 28: 751-755.
-
(1998)
Hepatology
, vol.28
, pp. 751-755
-
-
-
27
-
-
0032879468
-
Prognosis of hepatocellular carcinoma: The BCLC staging classification
-
Llovet JM, Bru C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
-
(1999)
Semin Liver Dis
, vol.19
, pp. 329-338
-
-
Llovet, J.M.1
Bru, C.2
Bruix, J.3
-
28
-
-
0021965806
-
Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients
-
DOI 10.1002/1097-0142(19850815)56:4 <918::AID-CNCR2820560437>3.0. CO;2-E
-
Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56: 918-928. (Pubitemid 15228292)
-
(1985)
Cancer
, vol.56
, Issue.4
, pp. 918-928
-
-
Okuda, K.1
Ohtsuki, T.2
Obata, H.3
-
29
-
-
0037086560
-
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients
-
DOI 10.1002/cncr.10384
-
Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002; 94: 1760-1769. (Pubitemid 34241115)
-
(2002)
Cancer
, vol.94
, Issue.6
, pp. 1760-1769
-
-
Leung, T.W.T.1
Tang, A.M.Y.2
Zee, B.3
Lau, W.Y.4
Lai, P.B.S.5
Leung, K.L.6
Lau, J.T.F.7
Yu, S.C.H.8
Johnson, P.J.9
-
30
-
-
0346896573
-
AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: Consensus statement
-
DOI 10.1080/13651820310015833
-
Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T,. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003; 5: 243-250. (Pubitemid 38008080)
-
(2003)
HPB
, vol.5
, Issue.4
, pp. 243-250
-
-
Henderson, J.M.1
Sherman, M.2
Tavill, A.3
Abecassis, M.4
Chejfec, G.5
Gramlich, T.6
-
31
-
-
7044231396
-
Hepatocellular carcinoma: Recent trends in the United States
-
DOI 10.1053/j.gastro.2004.09.013, PII S0016508504015926
-
El-Serag HB,. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004; 127: S27-S34. (Pubitemid 39423367)
-
(2004)
Gastroenterology
, vol.127
, Issue.SUPPL.
-
-
El-Serag, H.B.1
-
32
-
-
79953185045
-
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
-
Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011; 128: 2436-2443.
-
(2011)
Int J Cancer
, vol.128
, pp. 2436-2443
-
-
Ertle, J.1
Dechene, A.2
Sowa, J.P.3
-
33
-
-
55549106451
-
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?
-
Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ,. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med. 2008; 132: 1761-1766.
-
(2008)
Arch Pathol Lab Med
, vol.132
, pp. 1761-1766
-
-
Guzman, G.1
Brunt, E.M.2
Petrovic, L.M.3
Chejfec, G.4
Layden, T.J.5
Cotler, S.J.6
-
34
-
-
84055193440
-
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
-
Hashimoto E, Tokushige K,. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012; 42: 1-14.
-
(2012)
Hepatol Res
, vol.42
, pp. 1-14
-
-
Hashimoto, E.1
Tokushige, K.2
-
35
-
-
84863340542
-
Recent trend of clinical features in patients with hepatocellular carcinoma
-
Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012; 42: 368-375.
-
(2012)
Hepatol Res
, vol.42
, pp. 368-375
-
-
Nagaoki, Y.1
Hyogo, H.2
Aikata, H.3
-
36
-
-
63349085247
-
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis
-
Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009; 49: 851-859.
-
(2009)
Hepatology
, vol.49
, pp. 851-859
-
-
Paradis, V.1
Zalinski, S.2
Chelbi, E.3
-
37
-
-
70049084375
-
Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics
-
Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD,. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009; 3: 353-367.
-
(2009)
Expert Rev Gastroenterol Hepatol
, vol.3
, pp. 353-367
-
-
Shariff, M.I.1
Cox, I.J.2
Gomaa, A.I.3
Khan, S.A.4
Gedroyc, W.5
Taylor-Robinson, S.D.6
-
38
-
-
73149120271
-
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
-
Siegel AB, Zhu AX,. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009; 115: 5651-5661.
-
(2009)
Cancer
, vol.115
, pp. 5651-5661
-
-
Siegel, A.B.1
Zhu, A.X.2
-
39
-
-
79960747094
-
Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database
-
Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA,. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54: 463-471.
-
(2011)
Hepatology
, vol.54
, pp. 463-471
-
-
Welzel, T.M.1
Graubard, B.I.2
Zeuzem, S.3
El-Serag, H.B.4
Davila, J.A.5
McGlynn, K.A.6
|